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Abbreviation 
 
Following abbreviations have been used throughout. 
Ac acetyl 
ATR attenuated total reflection 
Bop (benzotriazol-1-yloxy)-tris(dimethylamino)phosphonium 
hexafluorophosphate 
br broad (in spectra) 
Bu butyl 
Cbz benzyloxycarbonyl 
d doublet (in spectra) 
d scale (NMR), dimensionless 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC 1,3-dicyclohexylcarbodiimide 
DEAD diethylazodicarboxylate 
DHP 3,4-dihydro-2H-pyran 
DIC diisopropylcarbodiimide 
DIEA diisopropylethylamine 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
e.g. for example 
equiv equivalent 
Et ethyl 
EP prostaglandin E 
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et al. and others (et all) 
FKBP FK506 binding protein 
g gram 
h hour 
Het heterocycle 
HIV human immunodeficiency virus 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrum 
5-HT 5-hydroxytryptamine 
HTS high-throughput screening 
Hz hertz (s-1) 
i iso 
i.e. that is (id est) 
IKK2 IkB kinase 2 
IR infrared 
LRMS low resolution mass spectrum 
m multiplet (in spectra) 
m meta 
M mol/dm3 
Me methyl 
min minute 
MS mass spectrum 
m/z mass-to-charge ratio 
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n normal 
NMM N-methylmorpholine 
NMP 1-methyl-2-pyrrolidinone 
NMR nuclear magnetic resonance 
Ns 2-nitrobenzenesulfonyl 
o ortho 
ODS octadecyl silica 
p para 
Ph phenyl 
PNMT phenylethanolamine N-methyltransferase 
Pr propyl 
PyBop benzotriazol-1-yl-oxytripyrro-lidinophosphonium hexafluorophosphate 
PyBrop bromo-tris-pyrrolidino-phosphonium hexafluorophosphate 
q quartet (in spectra) 
ref reference 
RyR ryanodine receptor 
s singlet (in spectra) 
SN2 bimolecular nucleophilic substitution 
t tripret (in spectra) 
TACE TNF-α converting enzyme 
TBAF tetrabutylammonium fluoride 
TBS tert-butyldimethylsilyl 
tert tertiary 
TFA trifluoroacetic acid 
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THF tetrahydrofuran 
TMAD N,N,N',N'-tetramethylazodicarboxamide 
Tr triphenylmethyl (trityl) 
VLA-4 very late antigen-4 
17b-HSD II type II 17b-hydroxysteroid dehydrogenase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5
Chapter 1 
 
General Introduction 
 
1. Chemical libraries including heterocycles 
Heterocycles, e.g., piperazine, pyrimidine, are virtually present in every class of known 
drugs (Figure 1).1 These cyclic structures mostly serve as scaffolds for the correct spatial 
positioning of pharmacophoric substituents and/or are parts of the pharmacophore itself.  
 
 
Figure 1-1. Structures of several known drugs. 
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Therefore, chemical libraries, which have the structures as scaffolds, are expected to play 
important roles on finding novel compounds with pharmacological activities. 
Chemical libraries including heterocyclic structures are generally constructed according 
to a flow diagram described in Figure 1-2. Heterocyclic structures extracted from the 
existing biologically active compounds are used as scaffolds of chemical libraries. 
 
N N
O
N
N N
N N
O
R2
R1
R3
N R1
R2
R3
N N
R1
R2
Biologically active compounds
Extraction of heterocyclic structures
...
...
Construction of chemical libraries
using heterocyclic structures
as scaf folds
 
Figure 1-2. Construction of chemical libraries based on heterocyclic structures. 
 
So far, many reports have reported the construction of chemical libraries based on the 
strategy described above (Figure 1-3). For example, Yu and co-workers reported libraries 
of 3,5,6-substituted 2-pyridone derivatives,2 which are contained in the chemical structures 
of specific non-nucleoside reverse transcriptase inhibitors of human immunodeficiency 
virus-1 (HIV-1) and cardiotonic agents for the treatment of heart failure.3, 4 In addition, 
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synthetic examples of libraries based on 1,4-benzodiazepine5, 6 and imidazole7, 8 were also 
reported.  
 
 
Figure 1-3. Existing libraries based on heterocyclic structures. 
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2. Synthetic strategy of chemical libraries including heterocycles 
Two synthetic methods, namely conventional solution-phase method and solid-phase 
method, are used for synthesizing chemical libraries, although both methods have 
inevitable drawbacks, respectively. Solution-phase methods are inappropriate for the 
multi-step syntheses of the libraries due to tedious purification required in each step. On 
the other hand, solid-phase methods can omit the purification of synthetic intermediates 
but generate the final products with polar resin-tethering substituents. For example, 
compounds synthesized by using well-known Wang resin and DHP resin have carboxyl 
and hydroxyl groups as traces, respectively (Scheme 1-1). Such polar and metabolically 
labile functional groups often compromise bioavailability and reduce structural diversity of 
the chemical libraries.  
 
 
Scheme 1-1. 
 
In addition, the cleavage reactions from the resin in the final step often give mixtures of 
desired compounds with many kinds of impurities generated by incomplete reactions on 
the polymer support in the previous steps. Therefore, purification after cleavage can not 
always provide the desired compounds in high purity (Scheme 1-2). 
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Scheme 1-2. 
 
To overcome such disadvantage of conventional solid-phase synthesis and construct 
chemical libraries of heterocycles efficiently, cyclization-cleavage approaches are 
recognized highly valuable methods of solid-phase synthesis. One of advantages of the 
approach is that only the desired cyclic compounds are detached from solid supports 
(Scheme 1-3). The byproducts generated from incomplete and/or undesired reactions 
remain on solid supports. Consequently, these methods can provide the desired 
heterocycles in high purity without time-consuming purification steps like column 
chromatography. This preferable property regarding purification is quite suitable to 
construct chemical libraries consisting of large number of compounds. Another advantage 
is that desired compounds can be obtained on “traceless way” which leaves no evidence of 
resin attachment in the final products. This property is very important because polar 
functional groups as traces often have a dramatically negative outcome on the medicinal 
efficacy of the final products. 
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Scheme 1-3. 
 
Recently several cyclization-cleavage approaches have been reported. The groups of 
Matthews and Kim elaborated strategies towards 1,3,5-trisubstituted hydantoins by 
employing mild base catalysis in the final step (Scheme 1-4).9 The primary amine of amino 
acids loaded on Wang resin was treated with triphosgene and a broad range of aliphatic 
and aromatic primary amines to obtain ureas as hydantoin precursors. Addition of mild 
bases such as Et3N liberated the 1,3,5-trisubstituted hydantoins in 48-100% yield, 
generally as a single peak on HPLC.  
 
 
Scheme 1-4. 
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Concurrently, the groups of Smith and Martinez reported a similar cyclization-cleavage 
approach towards quinazoline-2,4-diones (Scheme 1-5).10 In order to improve solvation 
properties, Smith, et al., introduced a triethyleneglycol spacer unit between the polystyrene 
matrix and the starting activated carbonate (i.e. chloroformate), while Martinez et al. 
started with the mixed carbonate resin from p-nitrophenol and hydroxymethyl polystyrene. 
Anthranilic acids were reacted with activated resin-bound mixed carbonates, followed by 
PyBOP or BOP mediated amidation of the benzoic acid moieties with several aliphatic or 
aromatic primary amines. Cyclization-cleavage was accomplished under high temperatures 
(DMF, 125 oC) or by using base catalysis at elevated temperatures (Et3N, MeOH, 125 oC,) 
to give the 1,3-disubstituted- (Smith) or 3-substituted-quinazoline-2,4-diones (Martinez). 
The yields were 22-72% with purities generally exceeding 95%.  
 
 
Scheme 1-5. 
 
Ganesan et al. showed that isatoic anhydrides can be transformed into 
4-hydroxyquinolin-2(1H)ones in a two step procedure via Wang resin bound cyanoacetate 
(Scheme 1-6).11 Reaction of the resin-bound activated methylene compound with isatoic 
  12 
anhydrides employing Et3N as a base proceeded smoothly at room temperature. After 
washing away the excess reagents, cyclization was effected by heating the resins in toluene 
at 80 oC to give the 4-hydroxyquinolin-2(1H)ones in yields of 22-65% with purities 
ranging from 72-99%. 
 
 
Scheme 1-6. 
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3. Development of new solid-phase methods for heterecycles based on 
cyclization-cleavage approaches  
Besides examples described above, several heterocycles were reported to be successfully 
synthesized via cyclization-cleavage approaches, while most of them utilized 
intramolecular aminolysis of the resin-bound ester by the terminal amine as ring-closing 
reactions (Scheme 1-7).  
 
 
Scheme 1-7. 
 
To construct more various heterocycles and expand diversity of chemical libraries for a 
purpose of raising hit rates of HTS, the author has embarked upon development of new 
solid-phase methods for heterecycles based on cyclization-cleavage approaches.  
In chapter 2 and 3 is described traceless solid-phase syntheses of 1,4-diazepan-2-ones 
and 1,4-diazabicyclo[3.3.1]octan-3-ones via ‘intramolecular cyclization to form cyclic 
N-benzyl quaternary ammonium salts’ followed by ‘selective cleavage of their N-benzyl 
group to release cyclic tertiary amines from solid supports’ (Scheme 1-8).  
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Scheme 1-8. 
 
Chapter 4 and 5 deals with thiomorpholin-3-ones and 4-sulfonyl-1,4-thiazaperhydroines 
as cyclic sulfides, which are provided by similar synthetic approach described above 
(Scheme 1-9). 
 
 
Scheme 1-9. 
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Chapter 2 
 
Traceless Solid-Phase Synthesis of 1,4-Diazepan-2-ones 
 
 
Abstract: A novel synthesis of 1,4-diazepan-2-ones using a traceless solid phase approach 
is described, in which many kinds of 1,4-diazepan-2-one have been efficiently obtained in 
high purity. The strategy is based on an intramolecular alkylation of tertiary amines, 
followed by elimination of the desired tertiary amines from the generated quaternary 
ammonium salts. 
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1. Introduction 
Compounds having a 1,4-diazepan-2-one (Figure 2-1) skeleton have been known to 
show intriguing biological activities, e.g., antagonism on muscarinic receptors, inhibition 
of platelet aggregation, inhibition of HIV protease, inhibition of bacterial translocase 
(Figure 2-2).1 Therefore this skeleton is very attractive as a template of chemical libraries 
to generate new bioactive compounds in high-throughput screenings. Compounds 2-1 have 
been synthesized using conventional solution-phase methods (Scheme 2-1),2 although 
these methods are not applicable for multi-step syntheses of libraries, due to the 
purification required in each step.  
On the other hand, efficient traceless syntheses of tertiary amines on polymer supports 
suitable for library syntheses have been reported.3 However, no library synthesis of tertiary 
amines having the 1,4-diazepan-2-one skeleton has been reported.  
In relation to the research to find new drug candidates from chemical libraries, the author 
developed an efficient traceless solid-phase synthesis of 1,4-diazepan-2-one derivatives via 
elimination of tertiary amines from quaternary ammonium salts on a polymer support. 
 
N
N
O
R4
R1
R2
R3
2­1  
Figure 2-1. 1,4-Diazepan-2-ones. 
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Figure 2-2. Bioactive 1,4-diazepan-2-ones. 
 
 
Scheme 2-1. Conventional solution-phase synthesis of a 1,4-diazepan-2-one derivative.2d 
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2. Results and Discussion 
In many cases of multi-step solid-phase syntheses, products obtained by cleavage of the 
resin in the final step are often mixtures of the desired compounds, along with many 
impurities generated by incomplete reactions on the polymer support in the previous steps. 
In our strategy depicted in Scheme 2-2, the author expected that the debenzylation of 
quaternary ammonium salts by an SN2 reaction could afford products in high purity 
without time-consuming purification steps such as column chromatography. By-products 
generated from incomplete and/or undesired reactions would remain on the solid support.4 
For instance, while the last debenzylation step might be accompanied by an SN2 reaction at 
the a-position of the carbonyl group, the by-products generated from such an undesirable 
reaction would remain bound to the solid support and not reduce the purity of the products. 
In addition, all of the assumed unreacted intermediates would not be detached from the 
solid support at the end of the reaction scheme. 
 
 
Scheme 2-2. 
 
The synthesis began with Mitsunobu reaction on 4-hydroxymethyl polystyrene 2-2 with 
N-monosubstituted 2-nitrobenzenesulfonamides 2-3 (Scheme 2-3).5,6 Next, N, N- 
disubstituted 2-nitrobenzenesulfonamides 2-4 provided the secondary amines 2-5 by 
deprotection of the 2-nitrobenzenesulfonyl (Ns) group. Next, by Michael addition, 2-5 
were transformed into b-amino ketones 2-7, which were then converted to the 
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corresponding diamines 2-9 by reductive amination. Diamines 2-9 were transformed into 
the key intermediates 2-11 by acylation with a-haloacetic acids 2-10. Intramolecular 
cyclization and the quaternarization of the resin-bound tertiary nitrogen were carried out in 
the presence of CsI in dioxane-H2O at 95 ºC. The products 2-12 were treated with thiols 
under conditions reported in the literature7a to provide the desired compound 2-1 in high 
purity without column chromatography purification. 
 
 
Scheme 2-3. (a) 2-3, PPh3, DEAD, THF, rt, 16 h; (b) HOCH2CH2SH, DBU, DMF, rt, 1 h; 
(c) 2-6, ClCH2CH2Cl, 40 ºC, 72 h; (d) 2-6, ClCH2CH2Cl, 80 ºC, 96 h; (e) NaBH(OAc)3, 
2-8, CH2Cl2, rt, 48 h; (f) DIC, 2-10, DMF, rt, 20 h; (g) PyBrop, 2-10, i-Pr2NEt, rt, 20 h; (h) 
CsI, dioxane, water, 95 ºC, 3 h; (i) HOCH2CH2SH, 2 N NaOH aq, EtOH, 70 ºC, 3 h; (j) 
HSCH2CO2H, 2 N NaOH aq, EtOH, 70 ºC, 3 h. 
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There have been some reports that N-benzyl groups of quaternary ammonium salts were 
cleaved by several nucleophiles (Scheme 2-4).7 Among them, the author chose thiolates 
because they have high nucleophilicity and can cleave N-benzyl groups of quaternary 
ammonium salts in relatively mild conditions and keep N-benzyl groups of primary, 
secondary and tertiary amines intact to afford products in high purity. 
 
 
Scheme 2-4. 
 
To demonstrate the usefulness of this approach, several 1,4-diazepan-2-one derivatives 
were synthesized and characterized. Representative results of these syntheses are shown in 
Table 2-1. Alkyl and aryl groups could be introduced at R1–R4 with high purities and 
moderate total yields, while compounds with functional groups such as basic nitrogen 
could also be obtained (Entry 9). It is worth noting that introduction of the benzyl groups 
at R1 (Entries 2–4) was also possible, but the yields were relatively low (Entries 3 and 4) 
under these conditions because nucleophilic attack during the last step might have 
occurred at R1 instead of the resin-bound benzyl group. Although 2-hydroxyethyl benzyl 
sulfides might be detached from solid supports under this cleavage condition, such 
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impurities can be removed by simple solid-phase-extraction based on cation exchange. 
Introduction of substituents at R4 gave mixtures of diastereomers. Unexpectedly, the 
major/minor diastereomer ratio exceeded 90:10 because epimerization might have 
occurred at the final cleavage step under the basic conditions at 70 ºC. Compound 2-1g 
having no substituents at R2 could not be prepared, probably due to the instability of the 
intermediate (Entry 7). Compound 2-1j lacking substituents at R3 was obtained by this 
route, though the yield was low (Entry 10). In this case, reductive amination of ketone 2-7 
with ammonia was needed. While many studies of reductive amination of ketones with 
primary and secondary amines on solid supports have been published, only one example 
using ammonia has been reported (Scheme 2-5).8 At first, the conditions shown in Scheme 
2-5 was applied to prepare diamine 2-9, but the reaction did not proceed at all. In fact, 
MeOH used as a solvent to dissolve NH4OAc was not suitable for solid-phase synthesis 
because of its low swelling property. The reductive amination was then successfully 
achieved by bubbling ammonia gas through the CH2Cl2 solution. This method could be 
widely applied to reductive amination on solid-phase synthesis.  
In conclusion, the author has demonstrated that 1,4-diazepan-2-one derivatives can be 
obtained in good yields and high purity based on the novel traceless solid-phase synthesis. 
This approach should be applicable to construct novel and diverse chemical libraries for 
high-throughput screenings to find the new compounds showing biological activities. 
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Table 2-1. Syntheses of 1,4-diazepan-2-one derivatives 2-1 
N
N
O
R4
R1
R2
R3  
 
a Isolated overall yields (7 steps) based on 2-2. b HPLC was carried out using a reverse phase column [ODS, 
eluent: CH3CN/20 mM phosphate buffer (pH 6.5)]. Purity was determined by summation of integrated HPLC 
peak areas at 210 nm. c HPLC was carried out using a column with a chiral stationary phase (Chiralpak IA, 
eluent: hexane/2-PrOH) because a reverse phase column (ODS) could not achieve separation of 
diastereomers. Ratio of the diastereomers was determined by summation of integrated HPLC peak areas at 
210 nm. d Condition j gave a slightly higher purity of 92% than condition i (purity of 89%). 
 
 
Scheme 2-5. 
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Experimental Section 
 
Typical experimental procedure is as follows:  
 
To a mixture of alkoxy resin 2-2 (18.0 g, 36 mmol, Polymer Laboratories; 2.0 mmol/g), 
N-[2-(4-bromophenyl)ethyl]-2-nitrobenzenesulfonamide 2-3 (27.7 g, 72 mmol) and PPh3 
(18.9 g, 72 mmol) in THF (300 ml) was added a 40% toluene solution of DEAD (33.3 ml, 
72 mmol) at 0 ºC. After stirring for 5 min, the whole was allowed to stir at room 
temperature for 20 h. The resin was washed with CH2Cl2 (x5), THF (x5), MeOH (x5), 
THF (x5), Et2O (x5) and MeOH (x5) to give 2-4. To the resin 2-4 in DMF (500 ml) was 
added DBU (53.8 ml, 360 mmol) and sulfanylethanol (25.2 ml, 360 mmol) at 0 ºC. After 
stirring for 2 min, the whole was allowed to stir at room temperature for 1 h. The resin was 
washed with Et3N-water (1:9, x3), DMF (x3), water (x5), MeOH (x5), THF (x5), Et2O 
(x5) and MeOH (x5) and was dried in vacuo (2-5: 24.8 g; equivalent to 1.45 mmol/g). To 
the resin 2-5 (413 mg, 0.6 mmol) in ClCH2CH2Cl (20 ml) was added but-1-en-3-one (0.95 
ml, 12 mmol). The whole was allowed to stir at 40 oC for 72 h. The resin was washed with 
CH2Cl2 (x5), THF (x5), Et2O (x5) and MeOH (x5). The resin 2-7 was suspended in a 
mixture of sodium triacetoxyborohydride (636 mg; 3 mmol), 2-(4-fluoropheny)ethylamine 
(334 mg; 2.4 mmol) and CH2Cl2 (10 ml) and stirred at room temperature for 48 h, then 
diluted with Et3N (2 ml) and water (10 ml). The resin washed with Et3N-water (1:9, x3), 
water (x3), MeOH (x3), CH2Cl2 (x5), Et2O (x5) and MeOH (x5) to give 2-9. Obtained 
resin 2-9 was swollen with a mixture of chloroacetic acid (680 mg; 7.2 mmol), 
diisopropylcarbodiimide (1.11 ml, 7.2 mmol), DMF (15 ml) and the mixture was agitated 
for 20 h at room temperature. Then the resin was washed with DMF (x5), Et3N-water (1:9, 
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x5), THF (x5) and MeOH (x5) to give 2-11. The resin 2-11 was swollen with a mixture of 
CsI (312 mg, 1.2 mmol), dioxane (16 ml) and water (4 ml) and stirred at 95 ºC for 3 h. 
Then to the mixture were added sulfanylethanol (540ml, 7.2 mmol), 2N NaOH (3 ml, 6 
mmol), and EtOH (20 ml) and the whole was allowed to stir at 70 ºC for 3 h. The resin was 
washed with MeOH-CHCl3 (1:4, x3) and EtOH (x5) and the filtrate was evaporated. The 
residue was partitioned between AcOEt and saturated aqueous NaHCO3. The organic layer 
was washed with brine and dried with Na2SO4 and evaporated. The residue was diluted 
with MeOH and the impurities generated from sulfanylethanol was removed by solid 
phase extraction (500 mg, Polymer Laboratories; PL-SO3H MP SPE) to provide product 
2-1a as a pale yellow oil (126 mg, 44%). 
 
All products gave satisfactory 400 MHz 1H NMR, 100 MHz 13C NMR, IR and MS 
spectra. The spectral data of 2-1 are given below: 
 
4-[2-(4-Bromophenyl)ethyl]-7-ethyl-1-[2-(4-fluorophenyl)ethyl]-1,4-diazaperhydroe
pin-2-one (2-1a). 1H NMR (400 MHz, DMSO-d6): d 7.45 (2H, d, J = 8.19 Hz), 7.29-7.24 
(2H, m), 7.17 (2H, d, J = 8.19 Hz), 7.10-7.06 (2H, m), 3.93-3.87 (1H, m), 3.49 (1H, d, J = 
15.62 Hz), 3.30-3.22 (2H, m), 3.09-3.00 (1H, m), 2.92-2.58 (8H, m), 1.83-1.60 (4H, m), 
0.84 (3H, t, J = 7.17 Hz); 13C NMR (100 MHz, CDCl3): d 11.7, 24.6, 28.0, 33.4, 33.5, 50.1, 
51.4, 55.8, 59.7, 60.7, 115.2 (d, J = 21.1 Hz), 119.8, 130.2 (d, J = 7.7 Hz), 130.5, 131.4, 
134.8 (d, J = 3.2 Hz), 139.1, 161.5 (d, J = 242.5 Hz), 172.3; IR (KBr) nmax: 2938, 1627, 
1509, 1222, 824, 511; MS: m/z 447/449 [M+H]+. 
 
4-[2-(4-Bromophenyl)methyl]-7-ethyl-1-[2-(4-fluorophenyl)ethyl]-1,4-diazaperhydr
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oepin-2-one (2-1b). 1H NMR (400 MHz, DMSO-d6): d 7.51 (2H, d, J = 8.19 Hz), 
7.33-7.30 (2H, m), 7.21 (2H, d, J = 8.19 Hz), 7.15-7.11 (2H, m), 4.02-3.92 (1H, m), 
3.52-3.42 (3H, m), 3.21-3.06 (3H, m), 2.88-2.77 (3H, m), 2.64-2.57 (1H, m), 1.87-1.66 
(4H, m), 0.85 (3H, t, J = 7.42 Hz); 13C NMR (100 MHz, CDCl3): d 11.6, 24.8, 28.4, 33.5, 
49.4, 51.3, 58.8, 60.3, 60.6, 115.2 (d, J = 21.1 Hz), 121.0, 130.3 (d, J = 7.9 Hz), 130.5, 
131.5, 134.9 (d, J = 3.2 Hz), 137.3, 161.6 (d, J = 242.7 Hz), 172.2; IR (KBr) nmax: 2937, 
1627, 1509, 1487, 1221, 825; MS: m/z 433/435 [M+H]+. 
 
7-Ethyl-1-[2-(4-fluorophenyl)ethyl]-4-benzyl-1,4-diazaperhydroepin-2-one (2-1c). 
1H NMR (400 MHz, DMSO-d6): d 7.33-7.22 (7H, m), 7.16-7.11 (2H, m), 3.99-3.90 (1H, 
m), 3.54 (1H, d, J = 13.313.31 Hz), 3.48 (1H, d, J = 13.313.31 Hz), 3.44 (1H, d, J = 15.62 
Hz), 3.313.31-3.27 (1H, m), 3.21 (1H, d, J = 15.62 Hz), 3.11-3.04 (1H, m), 2.87-2.74 (3H, 
m), 2.62-2.56 (1H, m), 1.88-1.66 (4H, m), 0.85 (3H, t, J = 7.42 Hz); 13C NMR (100 MHz, 
CDCl3): d 11.6, 24.7, 28.3, 33.5, 49.2, 51.4, 59.6, 60.5, 60.6, 115.2 (d, J = 21.1 Hz), 127.2, 
128.3, 128.8, 130.3 (d, J = 7.8 Hz), 134.9 (d, J = 3.3 Hz), 138.3, 161.6 (d, J = 242.7 Hz), 
172.4; IR (KBr) nmax: 2968, 2938, 1628, 1510, 1221, 825, 700; MS: m/z 355 [M+H]+. 
 
7-Ethyl-1-[2-(4-fluorophenyl)ethyl]-4-[(4-methoxyphenyl)methyl]-1,4-diazaperhydr
oepin-2-one (2-1d). 1H NMR (400 MHz, DMSO-d6): d 7.33-7.29 (2H, m), 7.17-7.10 (4H, 
m), 6.87 (2H, d, J = 8.45 Hz), 3.98-3.89 (1H, m), 3.74 (3H, s), 3.48-3.25 (4H, m), 3.19 (1H, 
d, J = 15.62 Hz), 3.10-3.04 (1H, m), 2.86-2.74 (3H, m), 2.61-2.53 (1H, m), 1.86-1.66 (4H, 
m), 0.85 (3H, t, J = 7.42 Hz); 13C NMR (100 MHz, CDCl3): d 11.6, 24.7, 28.4, 33.5, 49.1, 
51.4, 55.2, 59.0, 60.3, 60.7, 113.7, 115.2 (d, J = 21.1 Hz), 130.0, 130.3 (d, J = 8.3 Hz), 
132.0, 135.0 (d, J = 3.1 Hz), 158.8, 161.6 (d, J = 242.6 Hz), 172.5; IR (KBr) nmax: 2937, 
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1624, 1509, 1247, 1221, 826; MS: m/z 385 [M+H]+. 
 
7-Ethyl-1-[2-(4-fluorophenyl)ethyl]-4-phenyl-1,4-diazaperhydroepin-2-one (2-1e). 
1H NMR (400 MHz, CDCl3): d 7.29-7.25 (2H, m), 6.88-6.78 (7H, m), 4.27 (1H, d, J = 
16.64 Hz), 4.22-4.15 (1H, m), 4.02 (1H, d, J = 16.64 Hz), 3.72-3.69 (1H, m), 3.37-3.29 
(1H, m), 3.00-2.93 (2H, m), 2.77-2.66 (2H, m), 1.80-1.54 (4H, m), 0.89 (3H, t, J = 7.42 
Hz); 13C NMR (100 MHz, CDCl3): d 11.6, 24.8, 28.2, 33.5, 44.6, 52.5, 56.5, 62.0, 113.3, 
115.1 (d, J = 20.9 Hz), 117.8, 129.5, 130.3 (d, J = 7.8 Hz), 134.9 (d, J = 3.1 Hz), 147.6, 
161.4 (d, J = 242.4 Hz), 172.7; IR (ATR) nmax: 2965, 2935, 1623, 1598, 1506, 1218, 752; 
MS: m/z 341 [M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-1-[2-(4-fluorophenyl)ethyl]-7-methyl-1,4-diazaperhydr
oepin-2-one (2-1f). 1H NMR (400 MHz, DMSO-d6): d 7.45 (2H, d, J = 8.45 Hz), 
7.29-7.24 (2H, m), 7.17 (2H, d, J = 8.45 Hz), 7.11-7.07 (2H, m), 3.74-3.67 (1H, m), 
3.58-3.52 (1H, m), 3.46 (1H, d, J = 15.62 Hz), 3.36 (1H, d, J = 15.62 Hz), 3.21-3.13 (1H, 
m), 2.95-2.88 (1H, m), 2.80-2.60 (7H, m), 1.90-1.80 (1H, m), 1.61-1.53 (1H, m), 1.21 (3H, 
t, J = 6.91 Hz); 13C NMR (100 MHz, CDCl3): d 17.4, 31.2, 33.4, 33.6, 50.1, 50.4, 56.4, 
59.5, 115.2 (d, J = 21.1 Hz), 119.8, 130.3 (d, J = 7.8 Hz), 130.5, 131.8, 134.9 (d, J = 3.1 
Hz), 139.1, 161.6 (d, J = 242.6 Hz), 172.4; IR (KBr) nmax: 2936, 1627, 1509, 1489, 1221, 
823; MS: m/z 433/435 [M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-7-ethyl-1-[4-(trifluoromethoxy)phenyl]-1,4-diazaperhy
droepin-2-one (2-1h). 1H NMR (400 MHz, DMSO-d6): d 7.46 (2H, d, J = 8.45 Hz), 7.37 
(2H, d, J = 8.70 Hz), 7.28 (2H, d, J = 8.70 Hz), 7.20 (2H, d, J = 8.45 Hz), 3.67-3.60 (2H, 
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m), 3.55 (1H, d, J = 15.36 Hz), 3.08-2.99 (1H, m), 2.89-2.70 (5H, m), 2.19-2.13 (1H, m), 
1.89-1.80 (1H, m), 1.72-1.61 (1H, m), 0.78 (3H, t, J = 7.17 Hz); 13C NMR (100 MHz, 
CDCl3): d 11.6, 25.0, 28.5, 33.4, 51.3, 59.6, 63.2, 119.2, 119.9, 121.7, 129.1, 130.6, 131.4, 
139.0, 147.6, 173.0; IR (KBr) nmax: 2939, 1648, 1508, 1262, 1163, 1262, 1163, 807; MS: 
m/z 485/487 [M+H]+. 
 
1-{[4-(Dimethylamino)phenyl]methyl}-4-[2-(4-bromophenyl)ethyl]-7-ethyl-1,4-diaza
perhydroepin-2-one (2-1i). 1H NMR (400 MHz, DMSO-d6): d 7.45 (2H, d, J = 8.19 Hz), 
7.17 (2H, d, J = 8.19 Hz), 7.09 (2H, d, J = 8.70 Hz), 6.63 (2H, d, J = 8.70 Hz), 4.94 (1H, d, 
J = 14.43 Hz), 3.84 (1H, d, J = 14.43 Hz), 3.54 (1H, d, J = 15.36 Hz), 3.41 (1H, d, J = 
15.36 Hz), 3.24-3.16 (2H, m), 2.86 (6H, s), 2.73-2.60 (5H, m), 1.72-1.53 (4H, m), 0.81 
(3H, t, J = 7.42 Hz); 13C NMR (100 MHz, CDCl3): d 11.7, 24.2, 27.6, 33.4, 40.6, 50.3, 
51.1, 55.6, 58.2, 59.7, 112.5, 119.7, 125.7, 129.6, 130.6, 131.3, 139.2, 149.9, 172.6; IR 
(KBr) nmax: 2937, 1616, 1523, 1488, 1351, 1126, 808; MS: m/z 458/460 [M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-7-ethyl-1,4-diazaperhydroepin-2-one (2-1j). 1H NMR 
(400 MHz, CDCl3): d 7.39 (2H, d, J = 8.19 Hz), 7.08 (2H, d, J = 8.19 Hz), 5.61 (1H, s), 
3.57 (1H, d, J = 15.11 Hz), 3.48 (1H, d, J = 15.11 Hz), 3.38-3.33 (1H, m), 3.16-3.11 (1H, 
m), 2.93-2.69 (5H, m), 1.79-1.70 (1H, m), 1.60-1.50 (3H, m), 0.98 (3H, t, J = 7.42 Hz); 
13C NMR (100 MHz, CDCl3): d 10.5, 28.9, 32.1, 33.4, 54.6, 55.2, 56.1, 58.9, 119.8, 130.5, 
131.4, 139.0, 174.7; IR (ATR) nmax: 2934, 1659, 1488, 1127, 810; MS: m/z 325/327 
[M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-7-ethyl-1-[2-(4-fluorophenyl)ethyl]-3-methyl-1,4-diazap
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erhydroepin-2-one (2-1k). 1H NMR (400 MHz, DMSO-d6): d 7.44 (2H, d, J = 8.19 Hz), 
7.27-7.24 (2H, m), 7.16 (2H, d, J = 8.19 Hz), 7.12-7.08 (2H, m), 3.95-3.90 (1H, m), 
3.80-3.71 (1H, m), 3.61-3.52 (1H, m), 3.27-3.20 (1H, m), 3.05-2.90 (2H, m), 2.82-2.55 
(6H, m), 1.83-1.73 (1H, m), 1.65-1.47 (3H, m), 0.96-0.92 (6H, m); 13C NMR (100 MHz, 
CDCl3): d 12.2, 16.7, 26.4, 27.8, 35.2, 35.3, 44.9, 48.2, 50.9, 59.3, 59.4, 115.2 (d, J = 21.1 
Hz), 119.8, 130.1 (d, J = 7.8 Hz), 130.6, 131.3, 135.0 (d, J = 3.2 Hz), 139.2, 161.6 (d, J = 
242.7 Hz), 174.5; IR (KBr) nmax: 2938, 1639, 1509, 1221, 825, 522; MS: m/z 461/463 
[M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-7-ethyl-1-[2-(4-fluorophenyl)ethyl]-3-phenyl-1,4-diazap
erhydroepin-2-one (2-1l). 1H NMR (400 MHz, CDCl3): d 7.40-7.16 (9H, m), 7.01-6.91 
(4H, m), 4.93 (1H, s), 3.97-3.87 (1H, m), 3.40-3.25 (2H, m), 3.14-3.06 (1H, m), 2.97-2.82 
(5H, m), 2.72-2.69 (2H, m), 2.04-1.96 (1H, m), 1.49-1.25 (3H, m), 0.83 (3H, t, J = 7.30 
Hz); 13C NMR (100 MHz, CDCl3): d 11.8, 16.7, 25.6, 27.9, 34.1, 34.2, 44.2, 49.3, 53.5, 
59.7, 72.3, 115.2 (d, J = 21.0 Hz), 119.8, 127.1, 127.6, 128.1, 130.3 (d, J = 7.7 Hz), 130.5, 
131.3, 134.9 (d, J = 3.2 Hz), 138.8, 139.1, 161.6 (d, J = 242.6 Hz), 173.3; IR (ATR) nmax: 
2937, 1649, 1612, 1509, 1488, 1219, 1156, 1072, 1011, 824, 719, 698, 516; MS: m/z 
523/525 [M+H]+. 
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Chapter 3 
 
Traceless Solid-Phase Synthesis of 1,4-Diazabicyclo[3,.3.,1]octan-3-ones 
 
 
Abstract: A novel synthesis of 1,4-diazabicyclo[3,.3,.1]octan-3-one derivatives using a 
traceless solid-phase approach is described, in which many kinds of 
1,4-diazabicyclo[3,3,13.3.1]octan-3-one derivatives have been efficiently obtained in high 
purity, based on an intramolecular alkylation of tertiary amines followed by an elimination 
of desired tertiary amines from the generated quaternary ammonium salts. 
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1. Introduction 
1,4-Diazabicyclo[3,3,13.3.1]octan-3-one (3-1) skeleton is very attractive as a template of 
a chemical library for drug discovery because the structure is unique and can be easily 
functionalized to provide a diverse library. Recently, compounds having this skeleton have 
been reported to show antagonism on the substance P receptor.1 So far, 
1,4-Diazabicyclo[3,3,13.3.1]octan-3-ones (3-1) have been synthesized using conventional 
solution-phase methods.1,2 
Because of the high potency of this skeleton as a pharmacophore, the author intended to 
establish an efficient-traceless-solid-phase synthesis of 1,4-diazabicyclo[3,3,13.3.1]nonane 
derivatives via an elimination of cyclic tertiary amines from quaternary ammonium salts 
on polymer support in a similar way described in chapter 2. 
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Figure 3-1. 1,4-Diazabicyclo[3,3,13.3.1]octan-3-ones. 
 
 
Figure 3-2. Bioactive 1,4-diazabicyclo[3,3,13.3.1]octan-3-ones. 
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Scheme 3-1.2b 
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2. Results and Discussion 
In our strategy depicted in Scheme 2-2 on chapter 2, the author expected that only 
desired heterocycles were detached from the polymer support by debenzylation of cyclic 
quaternary ammonium salts via SN2 reaction and the byproducts generated from 
incomplete and/or undesired reactions remained on the polymer support. In this chapter, 
1,4-diazabicyclo[3,3,13.3.1]nonane derivatives were efficiently synthesized via similar 
way. 
The synthesis began with the amination of Merrifield resin 3-3 with the cyclic amines 
3-4 (Scheme 3-2). Next, the polymer-supported products were converted to the 
corresponding ketones 3-5, which provided the diamine 3-6 by reductive amination. Then 
3-6 were transformed into the key intermediates 3-7 by acylation with a-halo-acetic acids. 
The intramolecular cyclization, quaternarization of the tertiary nitrogen of the piperidine 
ring was carried out in the presence of n-Bu4NI in DMF at 120 ºC, which was higher 
temperature than that of 1,4-diazepan-2-ones described on chapter 2 due to the strain of a 
1,4-diazabicyclo[3,3,13.3.1]nonane structure. The products 3-8 were treated with 
mercaptoethanol under reported conditions to provide the desired compounds 3-2 in high 
purity without time-consuming purification steps like column chromatography. 
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Scheme 3-2. (a) 3-4, Et3N, n-Bu4I, DMF, 60 ºC, 24 h; (b) 6 N HCl aq., dioxane, rt, 2.5 h; 
(c) NaBH(OAc)3, R1NH2, CH2Cl2, rt, 48 h; (d) DIC, XCR2R3CO2H, DMF, rt, 20 h; (e) 
PyBrop, XCR2R3CO2H, i-Pr2NEt, rt, 20 h; (f) n-Bu4NI, DMF, 120 ºC, 5.5 h; (g) 
HOCH2CH2SH, 2 N NaOH aq., EtOH, 70 ºC, 3 h. 
 
To demonstrate the usefulness of this approach, several 
1,4-diazabicyclo[3,3,13.3.1]octan-3-one derivatives were synthesized and characterized by 
1HNMR and MS. The representative results are shown in Table 1. Alkyl and aryl groups 
can be introduced in R1 with high purities (>95%) and moderate or low total yields 
(5–51%) (Entries 1, 2, 3, 5), while a compound with basic nitrogen could be obtained 
(Entry 4). Effect of bulkiness of the substituents on a-position (R2, R3) of the carbonyl 
group on the yield was clearly observed (Entries 6 and 7), where monosubstitution is only 
successful, although disubstituted halide did not give the product. Construction of 
1,4-diazabicyclo[3,2,1]octan-3-one skeleton (Entry 8) was also possible and this result 
would expand the diversity of the libraries based on this synthetic route. 
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Table 3-1. Syntheses of 1,4-diazabicyclo[3,3,13.3.1]octan-3-one derivatives 3-2 
 
 
aIsolated overall yields (6 steps) based on Merrifield resin (3-3). 
bReverse-phase HPLC was carried out using CH3CN/20 mM phosphate buffer (pH 6.5). Flow rate: 1 mL/min. 
Column: ODS. HPLC purities were determined by summation of integrated HPLC peak areas at 220 or 210 
nm. 
 
In conclusion, the author has demonstrated that 1,4-diazabicyclo[3,3,13.3.1]octan-3-one 
derivatives can be obtained in good yields and high purity based on the novel traceless 
solid-phase synthesis. This approach should be applicable to construct novel and diverse 
chemical libraries for high-throughput screenings to find the new compounds showing 
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biological activities. 
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Experimental Section 
 
Typical experimental procedure is as follows:  
 
Merrifield resin 3-3 (51.9 g; 97.5 mmol, Polymer Laboratories; 1.88 mmol/g) was 
swollen with a mixture of DMF (600ml), 3,3-diethoxypiperidine 3-4 (n=1, 33.7 g, 195 
mmol), n-Bu4NI (2.4 g, 19.5 mmol) and the mixture was heated with slow stirring at 60 ºC 
for 24 h. The resin was washed with DMF (x5), DMF-water-Et3N-EtOH (2:2:2:1, x5), 
water (x5), and MeOH (x5) and was dried in vacuo (3-10: 65.4 g; 100%; equivalent to 1.49 
mmol/g). The resin 3-10 (805 mg; 1.2 mmol) was treated with 6 N HCl-dioxane (1:1, 10 
ml) at room temperature for 2.5 h. Then the resin was washed with water (x5), MeOH (x5), 
CH2Cl2 (x5), and Et2O (x5) to give 3-5. The resin 3-5 was suspended in a mixture of 
sodium triacetoxyborohydride (1.27 g; 6 mmol), 3-phenyl-1-propylamine (649 mg; 4.8 
mmol) and CH2Cl2 (20 ml) and stirred at room temperature for 48 h, then diluted with 
Et3N (2 ml) and water (10 ml). The resin washed with Et3N-water (1:9, x3), water (x3), 
MeOH (x3), CH2Cl2 (x5), and Et2O (x5) to give 3-6. Obtained resin 3-6 was swollen with 
a mixture of chloroacetic acid (1.36 g; 14.4 mmol), diisopropylcarbodiimide (2.23 ml, 14.4 
mmol), DMF (15 ml) and the mixture was agitated for 20 h at room temperature. Then the 
resin was washed with DMF (x5), Et3N-water (1:9, x5), CH2Cl2 (x5), MeOH (x5), and 
N-methylpyrrolidone (x5) to give 3-7. The resin 3-7 was swollen with a mixture of 
n-Bu4NI (456 mg; 3.6 mmol), N-methylpyrrolidone (10 ml) and stirred slowly at 120 ºC 
for 5.5 h. Then the resin was washed with DMF (x5), CH2Cl2 (x5), MeOH (x5), and EtOH 
(x5) to give 3-8. The resin was swallen with a mixture of mercaptoethanol (540 ml, 7.2 
mmol), 2 N NaOH (3 ml, 6 mmol), and EtOH (20 ml) and stirred at 70 ºC for 3 h. The 
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resin was washed with MeOH-CHCl3 (1:4, x3) and EtOH (x5) and the filtrate was 
evaporated. The residue was partitioned between AcOEt and saturated aqueous NaHCO3. 
The organic layer was removed. The aqueous layer was saturated with NaCl and washed 
with AcOEt. The combined organic washings were dried with Na2SO4 and evaporated. The 
residue was diluted with MeOH and the residual mercaptoethanol was removed by solid 
phase extraction (Varian Bond Elut, 1 g) to provide product 3-2b as a pale yellow oil (142 
mg, 46%). 
 
All products gave satisfactory 400 MHz 1H NMR and MS spectra. The spectral data of 
3-2 are given below: 
 
1,4-Diaza-4-benzylbicyclo[3.3.13.3.1]nonan-3-one (3-2a). 1H NMR (400 MHz, 
DMSO-d6): d 7.35-7.24 (5H, m), 4.97 (1H, d, J = 15.11 Hz), 4.09 (1H, d, J = 15.11 Hz), 
3.62 (1H, d, J = 18.18 Hz), 3.23-3.13-3.16 (2H, m), 2.98-2.84 (4H, m), 1.81-1.76 (1H, m), 
1.63-1.51 (2H, m), 1.32-1.23 (1H, m); MS: m/z 231 [M+H]+. 
 
1,4-Diaza-4-(3-phenylpropyl)bicyclo[3.3.13.3.1]nonan-3-one (3-2b). 1H NMR (400 
MHz, DMSO-d6): d 7.29-7.15 (5H, m), 3.75-3.68 (1H, m), 3.46 (1H, d, J = 17.92 Hz), 
3.40-3.30 (1H, m), 3.05 (1H, d, J = 17.92 Hz), 2.92-2.78 (5H, m), 2.56 (2H, t, J = 7.94 Hz), 
1.89-1.70 (3H, m), 1.63-1.45 (2H, m), 1.30-1.26 (1H, m); MS: m/z 259 [M+H]+. 
 
1,4-Diaza-4-(2-thienylmethyl)bicyclo[3.3.13.3.1]nonan-3-one (3-2c). 1H NMR (400 
MHz, DMSO-d6): d 7.42 (1H, dd, J = 5.12, 1.28 Hz), 7.04 (1H, dd, J = 3.58, 1.28 Hz), 
6.95 (1H, dd, J = 3.58, 5.12 Hz), 4.93 (1H, d, J = 14.89 Hz), 4.41 (1H, d, J = 14.89 Hz), 
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3.54 (1H, d, J = 18.18 Hz), 3.16 (1H, d, J = 18.18 Hz), 2.93-2.79 (4H, m), 1.84-1.74 (1H, 
m), 1.61-1.45 (2H, m), 1.29-1.23 (1H, m); MS: m/z 237 [M+H]+. 
 
1,4-Diaza-4-{[4-(dimethylamino)phenyl]methyl}bicyclo[3.3.13.3.1]nonan-3-one 
(3-2d). 1H NMR (400 MHz, DMSO-d6): d 7.10 (1H, d, J = 8.45 Hz), 6.67 (1H, d, J = 8.45 
Hz), 4.84 (1H, d, J = 14.59 Hz), 3.96 (1H, d, J = 14.59 Hz), 3.58 (1H, d, J = 17.92 Hz), 
3.22 (1H, m), 3.18 (1H, d, J = 17.92 Hz), 2.89 (4H, m), 2.86 (6H, s), 1.81-1.76 (1H, m), 
1.56-1.48 (2H, m), 1.29-1.25 (1H, m); MS: m/z 274 [M+H]+. 
 
1,4-Diaza-4-phenylbicyclo[3.3.13.3.1]nonan-3-one (3-2e). 1H NMR (400 MHz, 
DMSO-d6): d 7.45-7.38 (2H, m), 7.31-7.25 (3H, m), 3.73 (1H, m), 3.64 (1H, d, J = 18.18 
Hz), 3.64 (1H, d, J = 18.18 Hz), 3.313.31-3.26 (2H, m), 3.07-3.03 (1H, m), 2.96-2.93 (2H, 
m), 1.91-1.77 (1H, m), 1.69-1.54 (2H, m), 1.42-1.35 (1H, m); MS: m/z 217 [M+H]+. 
 
1,4-Diaza-2-methyl-4-benzylbicyclo[3.3.13.3.1]nonan-3-on (3-2f). 1H NMR (400 MHz, 
DMSO-d6): d 7.34-7.23 (5H, m), 4.97 (1H, d, J = 14.85 Hz), 4.02 (1H, d, J = 14.85 Hz), 
3.72-3.65 (1H, m), 3.63 (1H, q, J = 7.42 Hz), 3.23 (1H, m), 3.11-2.99 (3H, m), 2.76-2.68 
(1H, m), 1.87-1.79 (1H, m), 1.60-1.53 (1H, m), 1.48-1.32 (1H, m), 1.27 (3H, d, J = 7.42 
Hz), 1.23 (1H, m); MS: m/z 245 [M+H]+. 
 
1,4-Diaza-4-benzylbicyclo[3.2.1]octan-3-one (3-2h). 1H NMR (400 MHz, DMSO-d6): 
d 7.29-7.15 (5H, m), 4.81 (1H, d, J = 14.85 Hz), 4.08 (1H, d, J = 14.85 Hz), 3.70 (1H, m), 
3.50 (1H, d, J = 17.67 Hz), 3.08 (1H, m), 3.07 (1H, d, J = 17.67 Hz), 2.97-2.84 (2H, m), 
2,48-2,42 (1H, m), 1.89-1.85 (1H, m), 1.78-1.70 (1H, m); MS: m/z 217 [M+H]+. 
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Chapter 4 
 
Traceless Solid-Phase Synthesis of Thiomorpholin-3-ones 
 
 
Abstract: A novel synthesis of thiomorpholin-3-ones using a traceless solid-phase approach 
is described, in which many kinds of thiomorpholin-3-ones were efficiently obtained in 
high purity based on an intramolecular alkylation of sulfides followed by an elimination of 
desired thiomorpholin-3-ones from the generated sulfonium salts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  46 
1. Introduction 
Compounds having thiomorpholin-3-one skeletons (Figure 4-1) have been known to 
show intriguing biological activities, e.g., enhancement of brain noradrenaline and 
dopamine turnover (cognition enhancement),1 hypnotic activity,2 antagonism on 5-HT1b 
receptor,3 EP4 receptor,4 integrin a4b1,5 inhibition on nitric oxide synthase,6 calcium 
channel blockade,7 acne therapy,8 etc (Figure 4-2). Therefore, this skeleton is very 
attractive as a template for chemical libraries to generate newly-bioactive compounds on 
high-throughput screenings.  
Compounds 4-1 have been synthesized using conventional solution-phase methods 
(Scheme 4-1)2, 9, 10 and solid-phase methods (Scheme 4-2),11-13 although both methods 
have the drawbacks for synthesizing chemical libraries, which were described on chapter 1. 
In relation to the research to find new drugs from the chemical library, the author 
developed an efficient traceless solid-phase synthesis of thiomorpholin-3-ones. 
 
S
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O
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Figure 4-1. Thiomorpholin-3-ones. 
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Figure 4-2. Bioactive thiomorpholin-3-ones. 
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Scheme 4-1. Conventional solution-phase synthesis of a thiomorpholin-3-one derivative.9 
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Scheme 4-2. Conventional solid-phase synthesis of a thiomorpholin-3-one derivative.12 
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2. Results and Discussion 
The traceless solid-phase syntheses of cyclic tertiary amines were effected based on the 
selective debenzylation of N-benzyl quaternary ammonium salts as described in former 
chapters. This methodology was then successfully applied to construction of cyclic sulfide 
structures via S-benzyl sulfonium salts (Scheme 4-3). The results are shown below. 
 
 
Scheme 4-3. 
 
The synthesis began with the nucleophilic displacement of benzyl chloride on Merrifield 
resin 4-1 with the sulfanylethanols 4-2 (Scheme 4-4). Next, under the Mitsunobu 
conditions with N-monosubstituted 2-nitrobenzenesulfonamides 4-4,14 the 
polymer-supported alcohols 4-3 were converted to the N,N-disubstituted 
2-nitrobenzenesulfonamides 4-5, which provided the secondary amines 4-6 by the 
deprotection of the 2-nitrobenzenesulfonyl (Ns) group. Then 4-6 were transformed into the 
key intermediates 4-8 by acylation with chloroacetic acids 4-7. The intramolecular 
cyclization of 4-8 and the debenzylation of the sulfonium salts 4-9 were carried out in the 
presence of CsI, providing the product 4-10 in high purity without purification by column 
chromatography.  
If the polymer-supported alcohols 4-3 did not react with N-monosubstituted 
2-nitrobenzenesulfonamides 4-4 completely, the esters composed of the residual 4-3 and 
chloroacetic acids 4-7 might be formed in the amide formation steps (step d or e). The 
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esters then might lead to the formation of the lactones as impurities at the cleavage steps. 
Fortunately, such by-products have not been identified so far and the desired products were 
obtained with high purities, because the Mitsunobu reactions proceeded completely. The 
progress of these reactions were checked with the elemental analysis of the 
N,N-disubstituted 2-nitrobenzenesulfonamides 4-5 (data not shown). 
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Scheme 4-4. (a) 4-2, DBU, DMF, rt, 24 h; (b) 4-4, PPh3, DEAD, THF, rt, 16 h; (c) 
HOCH2CH2SH, DBU, DMF, rt, 1 h; (d) DIC, 4-7, DMF, rt, 20 h; (e) PyBrop, 4-7, i-Pr2NEt, 
rt, 20 h; (f) CsI, dioxane, water, 95 ºC, 1-2 h. 
 
While it was described in the chapter 2 and 3 that the cleavage of N-benzyl groups of 
quaternary ammonium salts needed the relatively strong nucleophiles like thiolates, there 
have been some reports that S-benzyl groups of sulfonium salts were cleaved by weak 
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nucleophiles like halogenide anions (Scheme 4-5).15 The author also found that S-benzyl 
groups of cyclization precursors 4-8 were simultaneously cleaved by a chloride or an 
iodide anion as cyclization.  
 
 
Scheme 4-5. 
 
To demonstrate the usefulness of this approach, several thiomorpholin-3-one derivatives 
were synthesized. The representative results are shown in Table 4-1. The alkyl and aryl 
groups can be introduced in R1 – R4 with high purities and moderate total yields (entries 
1-6), while compounds with functional groups such as ester and basic nitrogen could be 
obtained (entry 4, 5). Construction of a 7-membered and an 8-membered ring (entry 7, 8) 
was also possible, and this result would expand diversity of the libraries based on this 
synthetic route. 
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Table 4-1. Syntheses of thiomorpholin-3-one derivatives 4-10 
 
 
a Isolated overall yields (6 steps) based on Merrifield resin 4-1. 
bReverse-phase HPLC was carried out using CH3CN/20 mM phosphate buffer (pH 6.5). Flow rate: 1 mL/min. 
Column: ODS. HPLC purities were determined by summation of integrated HPLC peak areas at 210 or 220 
nm. 
 
In conclusion, the author has demonstrated that thiomorpholin-3-one derivatives and its 
analogs can be obtained in good yields and high purity based on the novel traceless 
solid-phase synthesis. This approach should be applicable to construct novel and diverse 
chemical libraries for high-throughput screenings to find the new compounds showing 
biological activities. 
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Experimental Section 
 
Typical experimental procedure is as follows:  
 
To Merrifield resin 4-1 (20.0 g, 38.8 mmol, Polymer Laboratories; 1.94 mmol/g) in 
DMF (200 ml) was added DBU (23.2 ml, 155mmol) and sulfanylethanol 4-2 (8.17 ml, 117 
mmol) at 0 ºC. After stirring for 10 min, the whole was allowed to stir at room temperature 
for 24 h. The resin was washed with DMF (x5), water (x5), MeOH (x5), THF (x5) and 
Et2O (x5) and was dried in vacuo (4-3: 22.3 g; 100%; equivalent to 1.74 mmol/g). To a 
mixture of the resin 4-3 (3.45 g, 6 mmol), 
N-[2-(4-Bromophenyl)ethyl]-2-nitrobenzenesulfonamide 4-4 (925 mg, 2.4 mmol) and PPh3 
(3.15 g, 12 mmol) in THF (100 ml) was added a 40% toluene solution of DEAD (5.56 ml, 
12 mmol) at 0 ºC. After stirring for 2 min, the whole was allowed to stir at room 
temperature for 16 h. The resin was washed with CH2Cl2 (x5), THF (x5), MeOH (x5), 
THF (x5) and Et2O (x5) to give 4-5. To the resin 4-5 (3.45 g, 6 mmol) in DMF (10 ml) was 
added DBU (1.79 ml, 12 mmol) and sulfanylethanol (842 ml, 12 mmol) at 0 ºC. After 
stirring for 2 min, the whole was allowed to stir at room temperature for 1 h. The resin was 
washed with Et3N-water (1:9, x3), DMF (x3), water (x5), MeOH (x5), THF (x5) and Et2O 
(x5) to give 4-6. The obtained resin 4-6 was swollen with a mixture of chloroacetic acid 
(1.36 g; 14.4 mmol), diisopropylcarbodiimide (2.23 ml, 14.4 mmol), DMF (12 ml) and the 
mixture was agitated for 20 h at room temperature. The resin was then washed with DMF 
(x5), Et3N-water (1:9, x5), THF (x5), MeOH (x5) to give 4-8. The resin 4-8 was swollen 
with a mixture of CsI (624 mg, 2.4 mmol), dioxane (8 ml) and water (2 ml) and stirred at 
95 ºC for 1 h. The resin was washed with MeOH-CHCl3 (1:4, x3) and MeOH (x5) and the 
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filtrate was evaporated. The residue was partitioned between AcOEt and saturated aqueous 
NaHCO3. The organic layer was washed with 10% aqueous Na2S2O3 and brine and dried 
with Na2SO4. The solvent was evaporated to provide a product 4-10a as a pale yellow 
solid (235 mg, 65%). 
 
All products gave satisfactory 400 MHz 1H NMR, 100 MHz 13C NMR, IR and MS 
spectra. The spectral data of 4-10 are given below: 
 
4-[2-(4-Bromophenyl)ethyl]-1,4-thiazaperhydroin-3-one (4-10a). 1H NMR (400 MHz, 
DMSO-d6): d 2.80-2.74 (4H, m), 3.20 (2H, s), 3.54-3.50 (4H, m), 7.21 (2H, d, J = 8.45 Hz), 
7.48 (2H, d, J = 8.45 Hz); 13C NMR (100 MHz, CDCl3): d 26.3, 30.3, 3.33, 50.1, 50.2, 
120.4, 130.6, 131.6, 137.8, 166.3; IR (KBr) nmax: 2933, 1652, 1484, 1425, 1362, 809, 515; 
MS: m/z 300/302 [M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-5,6-dimethyl-1,4-thiazaperhydroin-3-one (4-10b). 1H 
NMR (400 MHz, DMSO-d6): d 1.08 (0.8H, d, J = 6.40 Hz), 1.20 (0.8H, d, J = 6.40 Hz), 
1.27 (2.2H, d, J = 6.40 Hz), 1.33 (2.2H, d, J = 6.40 Hz), 2.91-2.71 (2H, m), 3.18-3.03 (2H, 
m), 3.32 (2H, s), 3.60-3.53 (1H, m), 3.85-3.75 (1H, m), 7.25-7.20 (2H, m), 7.52-7.47 (2H, 
m); 13C NMR (100 MHz, CDCl3): d 13.6, 17.3, 20.5, 20.8, 26.5, 30.2, 33.3, 33.4, 38.2, 
39.1, 49.3, 49.9, 60.3, 61.4, 120.3, 130.6, 131.6, 131.7, 137.7, 138.0, 165.1, 165.2; IR 
(KBr) nmax: 2975, 2930, 1628, 1488, 1428, 1404, 1072, 1012, 807, 510; MS: m/z 328/330 
[M+H]+. 
 
4-(4-Bromophenyl)-1,4-thiazaperhydroin-3-one (4-10c). 1H NMR (400 MHz, 
  55 
DMSO-d6): d 3.03 (2H, t, J = 5.63 Hz), 3.42 (2H, s), 3.96 (2H, t, J = 5.63 Hz), 7.29-3.26 
(2H, m), 7.60-7.56 (2H, m); 13C NMR (100 MHz, CDCl3): d 26.7, 30.6, 52.1, 120.6, 127.8, 
132.4, 141.6, 166.8; IR (KBr) nmax: 3056, 2930, 1656, 1489, 1396, 1011, 825, 551; MS: 
m/z 272/274 [M+H]+. 
 
4-{[4-(Dimethylamino)pheny]methyl}-1,4-thiazaperhydroin-3-one (4-10d). 1H NMR 
(400 MHz, DMSO-d6): d 2.75 (2H, t, J = 5.89 Hz), 2.86 (6H, s), 3.29 (2H, s), 3.48 (2H, t, J 
= 5.89 Hz), 4.42 (2H, s), 6.69-6.67 (2H, m), 7.10-7.08 (2H, m); 13C NMR (100 MHz, 
CDCl3): d 26.4, 30.4, 40.6, 48.0, 50.0, 112.6, 124.4, 129.3, 150.1, 166.4; IR (KBr) nmax: 
2932, 2812, 1648, 1533, 1442, 1365, 1189, 807, 586; MS: m/z 251 [M+H]+. 
 
Methyl 4-[(3-oxo-1,4-thiazaperhydroin-4-yl) methyl]benzoate (4-10e). 1H NMR (400 
MHz, DMSO-d6): d 2.84 (2H, t, J = 5.63 Hz), 3.36 (2H, s), 3.57 (2H, t, J = 5.63 Hz), 3.85 
(3H, s), 4.64 (2H, s), 7.40 (2H, d, J = 8.19 Hz), 7.94 (2H, d, J = 8.19 Hz); 13C NMR (100 
MHz, CDCl3): d 26.4, 30.5, 49.0, 50.6, 52.1, 127.8, 129.7, 130.1, 142.0, 166.6, 166.7; IR 
(KBr) nmax: 2988, 2948, 1726, 1649, 1436, 1416, 1282, 1112, 744; MS: m/z 266 [M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-2-methyl-1,4-thiazaperhydroin-3-one (4-10f). 1H NMR 
(400 MHz, DMSO-d6): d 1.21 (3H, t, J = 6.91 Hz), 2.79-2.70 (3H, m), 2.90-2.87 (1H, m), 
3.68-3.47 (5H, m), 7.21 (2H, d, J = 8.19 Hz), 7.48 (2H, d, J = 8.19 Hz); 13C NMR (100 
MHz, CDCl3): d 16.2, 26.4, 33.7, 36.1, 49.5, 50.3, 120.3, 130.6, 131.6, 137.9, 170.3; IR 
(KBr) nmax: 2977, 2933, 1655, 1488, 1451, 1425, 1072, 1011, 811, 508; MS: m/z 314/316 
[M+H]+. 
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4-[2-(4-Bromophenyl)ethyl]-1,4-thiazaperhydroepin-3-one (4-10g). 1H NMR (400 
MHz, DMSO-d6): d 1.80-1.75 (2H, m), 2.73 (2H, t, J = 7.94 Hz), 2.80 (2H, t, J = 5.63 Hz), 
3.32 (2H, s), 3.46-3.44 (4H, m), 7.21 (2H, d, J = 8.45 Hz), 7.47 (2H, d, J = 8.45 Hz); 13C 
NMR (100 MHz, CDCl3): d 29.1, 32.9, 33.8, 34.9, 50.1, 50.5, 120.2, 130.6, 131.6, 137.9, 
172.6; IR (KBr) nmax: 2931, 1642, 1486, 1448, 1422, 1133, 1011, 803, 512; MS: m/z 
314/316 [M+H]+. 
 
4-[2-(4-Bromophenyl)ethyl]-1,4-thiazaperhydroocin-3-one (4-10h). 1H NMR (400 
MHz, DMSO-d6): d 1.68-1.62 (2H, m), 1.87-1.81 (2H, m), 2.64 (2H, t, J = 5.12 Hz), 2.77 
(2H, t, J = 7.94 Hz), 3.35 (2H, s), 3.47-3.39 (4H, m), 7.21 (2H, d, J = 8.45 Hz), 7.48 (2H, d, 
J = 8.45 Hz); 13C NMR (100 MHz, CDCl3): d 28.9, 29.2, 29.8, 32.8, 33.3, 46.9, 47.2, 
120.2, 130.6, 131.6, 138.1, 171.1; IR (KBr) nmax: 2937, 1600, 1485, 1469, 1430, 1234, 
1129, 1070, 1010, 806, 516; MS: m/z 328/330 [M+H]+. 
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Chapter 5 
 
Traceless solid-phase synthesis of multiple sulfonamide-containing  
cyclic sulfides exploiting microwave irradiation 
 
 
Abstract: In this chapter, a new synthetic method of sulfonamide-containing cyclic sulfides 
using a microwave-assisted traceless solid-phase approach is described. Using this new 
method, many highly pure cyclic sulfides were efficiently synthesized based on 
intramolecular alkylation of the sulfides followed by elimination of the desired products 
from the generated sulfonium salts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  59 
1. Introduction 
Compounds having sulfonamide-containing cyclic sulfide skeletons (A-C, Figure 5-1) 
are known to show a number of intriguing biological activities, such as antimalarial effect,1 
VLA-4 antagonistic effect,2 RyR receptors modulatory effect,3 antiobesity effect,4 and 
inhibitory effect on matrix metalloproteinase,5 TACE,6 PNMT,7 FKBP12,8 carbonic 
anhydrase,9 IKK210 and 17b-HSD II11 (Figure 5-2). Therefore, it is believed that these 
skeletons and their analogs are very attractive templates for chemical libraries to generate 
novel bioactive compounds in high-throughput screenings (HTS). 
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Figure 5-1. Sulfonamide-containing cyclic sulfides. 
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Figure 5-2. Bioactive sulfonamide-containing cyclic sulfides. 
 
To generate a high rate of hits in HTS, diversity of compounds is extremely important. 
However, most reported chemical libraries are designed based on a single scaffold,12 the 
diversity of which is relatively low because all compounds in the library have the same 
structure as the scaffold. The most notable feature in this chapter is to construct highly 
diverse chemical libraries containing multiple scaffolds using the same synthetic approach. 
With respect to cyclic sulfide skeletons, our method can efficiently provide not only 
existing scaffolds1-11 (A-C, Figure 5-1) but also novel scaffolds (D-G, Figure 5-1) the 
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author first report herein, on the selection of appropriate building blocks. 
The cyclization-cleavage approach was also employed for the synthesis of 
sulfonamide-containing cyclic sulfides. This method is superior to the solution-phase 
synthesis in Scheme 5-1 with regard to easiness of purification.1-11 
 
O
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Scheme 5-1. Conventional solution-phase synthesis of a sulfonamide-containing cyclic 
sulfide derivative.5 
 
In the syntheses of thiomorpholin-3-ones as cyclic sulfides and two kinds of cyclic 
tertiary amines described in the former chapters,, intermediates possessing 
a-chloroacetamide moiety with strong alkylating activity were cyclized under mild 
conventional heating conditions. Because the cyclization precursors in Scheme 5-2 showed 
much weaker reactivity than those in chapter 4, microwave irradiation was used to 
promote the ring-forming reaction under higher temperature. Interestingly, conventional 
heating was not as effective as microwave irradiation as described below. A 
polymer-supported base was used as hydrogen chloride scavenger. 
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Scheme 5-2. 
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2. Results and Discussion 
The synthesis began with nucleophilic displacement of the benzyl chloride on Merrifield 
resin 5-1 with the sulfanylalchohols 5-2 (Scheme 5-3). Next, under the traditional 
Mitsunobu conditions with the N-Boc-protected sulfonamides 5-4, the polymer-supported 
alcohols 5-3 were converted to the N-alkyl-N-Boc-proctected sulfonamides 5-5. It was 
known that the Mitsunobu reaction with the unprotected primary sulfonamides using PPh3 
and DEAD gave the sulfonylphospha-l5-azenes in high yields (Scheme 5-4). Therefore 
N-Boc-protected sulfonamides 5-4 was applied for the Mitsunobu reaction13 to give 5-5. 
Treatment of 5-5 with n-BuNH2 then gave the deprotected sulfonamides 5-6.14 N-Boc 
groups are generally cleaved by TFA or other strong acids, which may cause decrease in 
yield and purity and restrict the number of avilable building blocks, thereby lowering 
diversity of the chemical library. To avoid these disadvantages, n-BuNH2 was adopted as a 
mild reagent for deprotection. 5-6 were then alkylated by the mono-TBS-protected diols 
5-7 under the improved Mitsunobu conditions with 
N,N,N’,N’-tetramethylazodicarboxamide (TMAD) and n-Bu3P.15 The resulting 5-9 were 
transformed into the alkyl halides 5-10. Intramolecular cyclization of 5-10 and 
debenzylation of the sulfonium salts 5-11 were carried out under microwave irradiation to 
provide the product 5-12 in high purity without purification by column chromatography. 
Initially, the last cyclization-debenzylation step was run by refluxing the mixed solvent of 
dioxane and water for 24 h in the presence of only CsI under conventinal heating condition. 
However, the product 5-12a was formed in only 25% yield, suggesting that more vigorous 
conditions were required to facilitate this reaction. The author then tried running the 
reaction in the microwave at 180 oC for 1 h and the yield increased to over 90%. Another 
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improvement of this reaction step was the addition of polymer-supported base, 
piperidinomethyl polystyrene, to scavenge the acids. Without the addition of the base, 
impurities generated by hydrolysis of resin-bound benzyl halides under the acidic 
conditions were detected by 1H NMR. Addition of triethylamine also gave a similar result 
regarding yield and purity, but the use of the polymer-supported base was much more 
convenient. 
 
 
Scheme 5-3. (a) 5-2, DBU, DMF, rt, 24 h; (b) 5-4, PPh3, DEAD, THF, rt, 24 h; (c) 
n-BuNH2, rt, 24 h; (d) 5-7, TMAD, n-Bu3P, THF, rt, 24 h; (e) 1M TBAF/THF, rt, 24 h; (f) 
Cl3CCCl3, PPh3, CH2Cl2, rt, 24 h; (g) CsI, piperidinomethyl polystyrene, dioxane, water, 
180 ºC (mW), 1-2 h. 
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Scheme 5-4. 
 
The cyclization reaction was also carried out under conventional heating conditions in a 
sealed tube at the same temperature (180 ºC) for the same reaction time (1 h) in order to 
assess the utility of microwave irradiation. Interestingly, microwave heating gave the much 
better yield of 5-12a (88%, Table 5-1, entry 1) than conventional heating (27%). It implied 
that the specific effect of microwave promoted cyclization and/or cleavage. There have 
been some other reports that the microwave enhancement can be attributed to its specific 
effect.16 Soufiaoui reported that the microwave acted the condensation of ethyl acetate or 
ethyl benzoylacetate with o-phenylenediamine by the specific effect, when microwave 
heating was compared with conventional heating under the same conditions of time and 
temperature (Scheme 5-5). Leadbeater found that microwave heating dramatically 
shortened the reaction time conventional heating needed under same temperature (Scheme 
5-6). It has been reported that the specific effect of microwave would be due to “hot spots” 
in samples irradiated with microwave.17 This is a thermal effect that arises as a 
consequence of the inhomogeneity of the applied field, resulting in the temperature in 
certain zones within the sample being much greater than the macroscopic temperature. 
These regions are not representative of the reaction conditions as a whole. While several 
authors have reported the specific effect of microwave described above, Kappe’s kinetic 
experiments has showed that there was no appreciable difference in reaction rates and 
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yields between reactions carried out under microwave irradiation and thermal heating at 
identical temperatures.18 It is understandable that all of reactions are not equally stimulated 
by microwave because hot spots may be created by the difference in dielectric properties 
of materials, which are unique to every reaction. 
 
 
Scheme 5-516a. 
 
 
Scheme 5-616b. 
To demonstrate the usefulness of this approach, several sulfonamide-containing cyclic 
sulfides were synthesized. The representative results are shown in Table 5-1. Various aryl 
and alkyl groups were introduced into R2 giving compounds with high purity and good 
total yield (entries 1-5). A compound with a functional group such as a basic nitrogen 
could also be obtained (entry 4). Construction of 7- and 8-membered rings (entry 6, 7) and 
condensed rings (entry 8-11), both of which are regarded as novel scaffolds, was also 
possible by switching the building blocks. This finding indicates that this synthetic route 
can expand diversity of the libraries without any difficulties, making the discovery of new 
bioactive compounds in HTS more favorable. 
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Table 5-1. Syntheses of sulfonamide-containing cyclic sulfides 5-12 
n
S
N
R1
S
R2O
O
R3
m  
 
a Isolated overall yields (7 steps) based on Merrifield resin 5-1. 
bReverse-phase HPLC was carried out using CH3CN/20 mM phosphate buffer (pH 6.5). Flow rate: 1 mL/min. 
Column: ODS. HPLC purities were determined by summation of integrated HPLC peak areas at 210 nm. 
 
It is generally known that solution-phase construction of medium-sized rings containing 
8- and 9-membered rings is often attended with undesirable intermolecular reactions and 
therefore tends to result in low yields or failure. By contrast, the author’s method afforded 
the 8- and 9-membered rings in yields comparable to those of the 6- and 7-membered rings 
(entry 1, 6 vs 7, 8, 11). The author hypothesized that the pseudo high-dilution effect on the 
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solid support probably favored the intramolecular cyclization over the intermolecular side 
reaction (Figure 5-3). Synthesis of 8-membered rings 5-12g by the solution-phase method 
was then carried out to compare the yield with that on the solid-phase and to check 
whether dimerization took place or not. Unexpectedly, no detectable amount of the dimmer 
5-15 could be identified and the yield of 5-12g by the solution-phase method was 
comparable to that on the solid-phase (Scheme 5-7).  
While the pseudo high-dilution effect on the solid support could not be confirmed in this 
case, Mazur had demonstrated earlier the interesting feature of the solid-phase synthesis 
(Scheme 5-8).19 o-Benzyne was generated by oxidation of 1-aminobenzotriazole derivative 
covalently bound to a resin. When lead tetraacetate was employed as the oxidizing agent, 
o-benzyne was converted to a mixture of isomeric aryl acetates. This reaction was not 
observed for 1-aminobenzotriazole on solution-phase, where dimerization was the 
predominant pathway. The results were explained by a low frequency of encounter 
between the resin-bound intermediates which allow the relatively slow acetate formation.  
 
 
Figure 5-3. The pseudo high-dilution effect on the solid support. 
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In the present study, the author did not observe the apparent pseudo high-dilution effect on 
the solid support. The author thought the present cyclization-cleavage approaches are thus 
inherently advantageous for the monomer formation. 
 
Scheme 5-7. 
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Scheme 5-8. 
In conclusion, the author has demonstrated that sulfonamide-containing cyclic sulfides 
can be obtained in good yields and high purity based on the novel traceless solid-phase 
synthesis. This approach should be applicable to construct novel and diverse chemical 
libraries for high-throughput screenings to find the new compounds showing biological 
activities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  71 
 
Experimental Section 
 
Typical experimental procedure is as follows:  
 
To Merrifield resin 5-1 (20.0 g, 38.8 mmol, Polymer Laboratories; 1.94 mmol/g) in 
DMF (200 ml) was added DBU (23.2 ml, 155mmol) and sulfanylethanol 5-2 (9.09 ml, 116 
mmol) at 0 ºC. After stirring for 10 min, the whole was allowed to stir at room temperature 
for 24 h. The resin was washed with DMF (x5), water (x5), MeOH (x5), THF (x5), Et2O 
(x5) and MeOH (x5) and dried in vacuo (5-3: 21.4 g; equivalent to 1.81 mmol/g). To a 
mixture of the resin 5-3 (11.9 g, 21.6 mmol), 
N-(tert-Butoxycarbonyl)-p-toluenesuflonamide 5-4 (23.4 g, 86.4 mmol) and PPh3 (22.7 g, 
86.4 mmol) in THF (200 ml) was added dropwise 40% toluene solution of DEAD (40 ml, 
86.4 mmol) at 0 ºC for 30 min. After stirring for 10 min, the whole was allowed to stir at 
room temperature for 24 h. The resin was washed with CH2Cl2 (x5), THF (x5), MeOH (x5), 
THF (x5), Et2O (x5) and MeOH (x5) and dried in vacuo (5-5: 21.4 g; equivalent to 1.17 
mmol/g). To the resin 5-5 (3.08 g, 3.6 mmol) was added n-BuNH2 (20 ml), and the whole 
was allowed to stir at room temperature for 24 h. The resin was washed with Et3N-DMF 
(1:4, x5), DMF (x5), CH2Cl2 (x5), THF (x5), Et2O (x5) and MeOH (x5) to give 5-6. To a 
mixture of the obtained resin 5-6, 2-(tert-Buthyldimethylsilanyloxy)ethanol 5-7 (2.54 g, 
14.4 mmol) and n-Bu3P (3.6 g, 14.4 mmol) in THF (200 ml) was added 
N,N,N’,N’-tetramethylazodicarboxamide (2.48 g, 14.4 mmol) at 0 ºC. After stirring for 10 
min, the whole was allowed to stir at room temperature for 24 h. The resin was washed 
with water (x3), DMF (x5), MeOH (x5), THF (x5), Et2O (x5) and MeOH (x5) to give 5-8. 
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To the resin 5-8 was added 1 M THF solution of TBAF (25 ml), and the whole was 
allowed to stir at room temperature for 24 h. The resin was washed with THF (x5), MeOH 
(x5), THF (x5) and MeOH (x5) to give 5-9. The obtained resin 5-9 was swollen with a 
mixture of PPh3 (3.78 g, 14.4 mmol), hexachloroethane (3.41 g, 14.4 mmol) and CH2Cl2 
(40 ml) and the mixture was stirred for 24 h at room temperature. The resin was then 
washed with CH2Cl2 (x5), MeOH (x5), THF (x5), Et2O (x5) and MeOH (x5) to give 5-10. 
To the resin 5-10 was added CsI (312 mg, 1.2 mmol), piperidinomethyl polystyrene (400 
mg, 1,2 mmol, Polymer Laboratories; 3.0 mmol/g), dioxane (12 ml) and water (3 ml). The 
mixture was then heated in a microwave at 180 ºC for 1 h. The resin was washed with 
water (x3), MeOH-CHCl3 (1:4, x3) and MeOH (x5) and the filtrate was evaporated. The 
residue was partitioned between AcOEt and saturated aqueous NaHCO3. The organic layer 
was washed with 10% aqueous Na2S2O3 and brine and dried with Na2SO4. The solvent was 
evaporated to provide product 5-12a as pale yellow solid (130 mg, 88%). 
 
All products gave satisfactory 400 MHz 1H NMR, 100 MHz 13C NMR, IR and HRMS 
spectra. The spectral data of 5-12 are given below: 
 
4-[(4-Methylphenyl)sulfonyl]-1,4-thiazaperhydroine (5-12a). 1H NMR (400 MHz, 
DMSO-d6): d 2.42 (3H, s), 2.64-2.67 (4H, m), 3.16-3.18 (4H, m), 7.46 (2H, d, J = 8.19 Hz), 
7.63 (2H, d, J = 8.19 Hz); 13C NMR (100 MHz, CDCl3): d 21.5, 27.3, 47.9, 127.5, 129.8, 
133.8, 143.8; IR (ATR) nmax: 1336, 1160, 894, 715, 703, 584, 545; HRMS (ESI): 
calculated for C11H16NO2S2 [M+H]+ 258.0616, found 258.0626. 
 
4-[(4-Methoxyphenyl)sulfonyl]-1,4-thiazaperhydroine (5-12b). 1H NMR (400 MHz, 
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DMSO-d6): d 2.65-2.67 (4H, m), 3.14-3.17 (4H, m), 3.86 (3H, s), 7.16 (2H, d, J = 8.70 Hz), 
7.67 (2H, d, J = 8.70 Hz); 13C NMR (100 MHz, CDCl3): d 27.3, 47.9, 55.6, 114.4, 128.3, 
129.5, 163.1; IR (ATR) nmax: 1258, 1156, 1093, 899, 853, 705, 583, 555; HRMS (ESI): 
calculated for C11H16NO3S2 [M+H]+ 274.0566, found 274.0578. 
 
4-{[(3-(Trifluoromethyl)phenyl]sulfonyl}-1,4-thiazaperhydroine (5-12c). 1H NMR 
(400 MHz, DMSO-d6): d 2.67-2.69 (4H, m), 3.26-3.29 (4H, m), 7.93 (1H, t, J = 7.94 Hz), 
7.99 (1H, s), 8.09 (1H, d, J = 7.94 Hz), 8.14 (1H, d, J = 7.94 Hz); 13C NMR (100 MHz, 
CDCl3): d 27.3, 47.9, 123 (q, J = 271 Hz), 124.3 (q, J = 3.80 Hz), 129.6 (q, J = 3.60 Hz), 
130.1, 130.5, 132.0 (q, J = 33.5 Hz), 138.4; IR (ATR) nmax: 1165, 1124, 1068, 693, 568; 
HRMS (ESI): calculated for C11H13NO2F3S2 [M+H]+ 312.0345, found 312.0334. 
 
4-{[(5-(Dimethylamino)naphthyl]sulfonyl}-1,4-thiazaperhydroine (5-12d). 1H NMR 
(400 MHz, DMSO-d6): d 2.59-2.62 (4H, m), 2.84 (6H, s), 3.43-3.45 (4H, m), 7.28 (1H, d, 
J = 7.68 Hz), 7.60-7.68 (2H, m), 7.12-7.13 (1H, m), 8.20 (1H, d, J = 8.70 Hz), 8.52 (1H, d, 
J = 8.45 Hz); 13C NMR (100 MHz, CDCl3): d 27.3, 45.4, 47.3, 115.3, 119.4, 123.1, 128.1, 
130.1, 130.3, 130.7, 133.5, 151.8; IR (ATR) nmax: 1318, 1080, 913, 568; HRMS (ESI): 
calculated for C16H21N2O2S2 [M+H]+ 337.1038, found 337.1030. 
 
4-(Benzylsulfonyl)-1,4-thiazaperhydroine (5-12e). 1H NMR (400 MHz, DMSO-d6): d 
2.55-2.57 (4H, m), 3.313.31-3.32 (4H, m), 4.43 (2H, s), 7.35-7.42 (5H, m); 13C NMR (100 
MHz, CDCl3): d 27.7, 48.0, 57.6, 128.7, 128.9, 130.4, 130.7; IR (ATR) nmax: 1149, 899, 
699, 528; HRMS (ESI): calculated for C11H16NO2S2 [M+H]+ 258.0616, found 258.0623. 
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4-[(4-Methylphenyl)sulfonyl]-1,4-thiazaperhydroepine (5-12f). 1H NMR (400 MHz, 
DMSO-d6): d 1.86-1.92 (2H, m), 2.39 (3H, s), 2.67-2.74 (4H, m), 3.32-3.41 (4H, m), 7.41 
(2H, d, J = 8.19 Hz), 7.69 (2H, d, J = 8.19 Hz); 13C NMR (100 MHz, CDCl3): d 21.8, 31.0, 
31.9, 35.5, 48.8, 53.8, 126.8, 129.7, 136.8, 143.2; IR (ATR) nmax: 1329, 1156, 714, 546; 
HRMS (ESI): calculated for C12H18NO2S2 [M+H]+ 272.0773, found 272.0787. 
 
4-[(4-Methylphenyl)sulfonyl]-1,4-thiazaperhydroocine (5-12g). 1H NMR (400 MHz, 
DMSO-d6): d 1.71-1.77 (2H, m), 1.85-1.91 (2H, m), 2.39 (3H, s), 2.71-2.73 (2H, m), 
2.90-2.93 (2H, m), 3.09-3.11 (2H, m), 3.29-3.32 (2H, m), 7.42 (2H, d, J = 7.94 Hz), 7.66 
(2H, d, J = 7.94 Hz); 13C NMR (100 MHz, CDCl3): d 21.5, 23.6, 27.0, 31.6, 33.5, 49.6, 
51.0, 127.2, 129.7, 134.9, 143.3; IR (ATR) nmax: 1324, 1155, 693, 647, 591, 546; HRMS 
(ESI): calculated for C13H20NO2S2 [M+H]+ 286.0929, found 286.0947. 
 
5-[(4-Methylphenyl)sulfonyl]-1H,3H,4H,6H-benzo[f]1,4-thiazaperhydroocine 
(5-12h). 1H NMR (400 MHz, DMSO-d6): d 2.42 (3H, s), 2.46-2.52 (2H, m), 3.49-3.52 (2H, 
m), 4.03 (2H, s), 4.42 (2H, s), 7.21-7.31 (4H, m), 7.44 (2H, d, J = 8.19 Hz), 7.73 (2H, d, J 
= 8.19 Hz); 13C NMR (100 MHz, CDCl3): d 21.5, 29.3, 32.9, 50.4, 51.0, 127.1, 127.7, 
129.1, 129.9, 130.5, 134.3, 136.0, 136.9, 143.6; IR (ATR) nmax: 1330, 1156, 718, 651, 543; 
HRMS (ESI): calculated for C17H20NO2S2 [M+H]+ 334.0929, found 334.0922. 
 
4-[(4-Methylphenyl)sulfonyl]- 2H,3H,5H-benzo[f]1,4-thiazaperhydroepine (5-12i). 
1H NMR (400 MHz, DMSO-d6): d 2.37 (3H, s), 2.77-2.79 (2H, m), 3.65-3.52 (2H, m), 
4.51 (2H, s), 7.27-7.32 (2H, m), 7.35 (2H, d, J = 7.94 Hz), 7.41-7.47 (2H, m), 7.60 (2H, d, 
J = 7.94 Hz); 13C NMR (100 MHz, CDCl3): d 21.5, 33.8, 52.3, 54.0, 127.0, 128.1, 128.2, 
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129.7, 130.4, 132.9, 136.0, 137.0, 142.1, 143.3; IR (ATR) nmax: 1327, 1149, 1090, 1071, 
1054, 553, 543; HRMS (ESI): calculated for C16H18NO2S2 [M+H]+ 320.0773, found 
320.0786. 
 
5-[(4-Methylphenyl)sulfonyl]- 2H,3H,4H,6H-benzo[g]1,5-thiazaperhydroocine 
(5-12j). 1H NMR (400 MHz, DMSO-d6): d 1.66-1.72 (2H, m), 2.41 (3H, s), 2.72-2.75 (2H, 
m), 3.30-3.36 (2H, m), 4.58 (2H, s), 7.32-7.45 (5H, m), 7.59 (1H, d, J = 7.68 Hz), 7.76 (2H, 
d, J = 8.45 Hz); 13C NMR (100 MHz, CDCl3): d 21.5, 29.3, 36.5, 47.1, 51.9, 127.1, 129.1, 
129.8, 131.5, 135.0, 136.6, 137.2, 141.7, 143.2; IR (ATR) nmax: 1154, 1092, 749, 715, 653, 
606; HRMS (ESI): calculated for C17H20NO2S2 [M+H]+ 334.0929, found 334.0917. 
 
12-[(4-Methylphenyl)sulfonyl]-6H,11H,13H-dibenzo[b,g]1,5-thiazaperhydroonine 
(5-12k). 1H NMR (400 MHz, DMSO-d6): d 2.45 (3H, s), 4.14 (2H, s), 4.21 (2H, s), 4.47 
(2H, s), 7.00-7.14 (5H, m), 7.21-7.29 (2H, m), 7.36-7.38 (1H, m), 7.48 (2H, d, J = 8.45 
Hz), 7.84 (2H, d, J = 8.45 Hz); 13C NMR (100 MHz, CDCl3): d 21.6, 37.9, 47.4, 49.7, 
127.3, 127.7, 128.3, 128.4, 128.6, 129.8, 130.3, 131.3, 131.4, 133.9, 134.8, 136.8, 137.4, 
137.7, 141.1, 143.4; IR (ATR) nmax: 1327, 1150, 909, 719, 614, 527; HRMS (ESI): 
calculated for C22H22NO2S2 [M+H]+ 396.1086, found 396.1074. 
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General Conclusion 
 
The studies described in this thesis are directed to the traceless solid-phase syntheses for 
heterocycles based on cyclization-cleavage approaches, which can provide the desired 
heterocycles in high purity without time-consuming purification steps and are quite 
preferable for the construction of the chemical libraries. 
While, on the basis of the approaches, the author developed the novel synthetic methods 
of two types of cyclic tertiary amines (1,4-diazepan-2-ones and 
1,4-diazabicyclo[3,3,13.3.1]octan-3-ones) and two types of cyclic sulfides 
(thiomorpholin-3-ones and sulfonamide-containing cyclic sulfides), it is expected that the 
other N- and S-containing heterocycles which have the druglike properties could also be 
synthesized via the similar strategy. Furthermore, while the syntheses described in this 
thesis were conducted manually, the automated systems could expectedly be adopted to 
further accelerate the syntheses based on the cyclization-cleavage approaches. 
Combination of the approaches and pool-split methods are also possible to make the 
libraries composed of huge number of compounds. 
Chemical libraries are important in the discovery of lead molecules which are active for 
various new targets validated from genomics and proteomics research. The strategy in this 
thesis contributes to constructing chemical libraries time- and cost-effectively and 
therefore, can stimulate the developments of the high-quality drug candidates. 
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Instrumentation and Method 
 
 The following details apply to all experimental parts of this thesis. 
IR spectra were recorded on a Perkin-Elmer 1640 spectrophotometer. 1H NMR and 13C 
NMR spectra were recorded on a Bruker AVANCE (400 MHz) spectrometer. Chemical 
shifts are reported in ppm downfield from an internal standard of tetramethylsilane. LRMS 
spectra were obtained on a Thermo-Fisher LXQ spectrometer. HRMS spectra were 
obtained on an Applied Biosystems QSTAR® Elite spectrometer. Analytical HPLC of the 
products was performed on an Agilent 1100 using a CERI L-column ODS. Microwave 
heating was conducted by a Biotage InitiatorTM which is a single-mode microwave reactor. 
TLC analyses were performed on commercial glass plates bearing 0.25 mm layer of Merck 
silica gel 60 F254. 
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